Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IDDO and MORU released its Medicine Quality Scientific Literature Surveyor. The surveyor delivers summaries of published scientific reports on the quality of the classes of essential medicines listed below, across regions and over time. We hope it will help medicine regulators, scientists, health professionals, purchasers and officials fill critical information gaps.

Africa and Asia map showing locations of Medicine Quality Scientific Literature Surveyor

Substandard and falsified (SF) medical products (medicines, vaccines, diagnostic tests and devices) pose an immediate danger to many people worldwide, and in the case of anti-infectives, they could also increase the threat of drug resistance emerging and spreading. A major challenge in preventing this is a lack of accessible and reliable information on how widespread they really are. This new mapping tool visualises these data and it will help scientists, health professionals and officials fill critical information gaps. 

Funded by Wellcome, the tool delivers summaries of published scientific reports on the quality of communicable diseases (antimalarials, antiretrovirals, antibiotics, anti-tuberculosis) non-communicable diseases (antidiabetics and medical devices for diabetes management, cardiovascular medicines and medical devices), veterinary medicines, and vaccines across regions and over time, both in English and French.

It builds on the success of the Medicine Quality team’s work on WWARN’s existing Antimalarial Surveyor and future phased releases are planned that will expand its reach to other medical products.  

With increasing number of reports in the scientific literature of substandard and falsified medical products for diagnosis, treatment and prevention of COVID-19 we are developing a Surveyor database and map for these, including past reports of SF medicines being repurposed for COVID-19.

Read more on the IDDO website

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.